MV BioTherapeutics SA
- Home
- Companies
- MV BioTherapeutics SA
- News
- Bio International Convention Digital ...
Bio International Convention Digital June 8-12, 2020
May. 25, 2020
Courtesy ofMV BioTherapeutics SA
Thanks to the support of Innosuisse, MV BioTherapeutics is participation at this important annual event within the Swiss Pavillon hosted and supported electronically by the Switzerland Global Enteprise (https://www.s-ge.com/en/sbh) .
We look forward meeting potential investors and licensing partners.
About MV BioTherapeutics
MV BioTherapeutics is a Swiss microbiome biotherapeutics company founded in 2018 as a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona. The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications:
- ApyraVax with the lead indication of Clostridioides difficile infection
- ApyraMed with lead indications as immune modulator in cancer and beneficial for the gut ecosystem
Research experiments and preclinical trials are performed in the research lab hosted at IRB. The company is looking for seed funding in order to move forward as a fully operational company into clinics with the main indications.
